<DOC>
	<DOCNO>NCT02699424</DOCNO>
	<brief_summary>This open-label , phase II trial patient PSA recurrence prostatectomy . Patients enter study receive initial 50 Gray ( Gy ) radiotherapy ( 25 x 2Gy ) prostate bed thereafter classify either responder non-responders depend PSA response fifth week radiotherapy . A 68-Ga- PSMA-PET do start radiotherapy , analyzed fifth treatment week order identify cancer lesion patient poor PSA response . Patients PSA response 5 week radiotherapy receive subsequent therapy , whilst patient poor PSA response may need additional therapy radiotherapy lymph node metastases and/or boost fraction local recurrence . Patients 3 lymph node metastasis distant metastasis receive radiotherapy , individualized systemic therapy start .</brief_summary>
	<brief_title>Prospective Evaluation 68-Ga-prostate Specific Membrane Antigen ( PSMA ) -Positron Emission Tomograph ( PET ) Early Prostatic Specific Antigen ( PSA ) Kinetics During Salvage Radiotherapy Personalizing Management Men With Relapse Prostate Cancer After Radical Prostatectomy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histological evidence prostate cancer radical prostatectomy specimen At least 2 rise PSA value , last ≥ 0.15 ng/ml Tumor , regional node , metastasis ( TNM ) : T , N0/x , M0/x Age : 18 year old World Health Organization ( WHO ) performance status 01 Life expectancy &gt; 10 year Adequate laboratory finding : hematological : hemoglobin &gt; 90 g/L ( may transfuse maintain exceed level ) absolute neutrophil count ( ANC ) ≥ 1,0 x 109/L , platelet ≥ 75 x 109/L hepatic : bilirubin ≤ 1.5 x upper limit normal ( ULN ) , alanine aminotransferase ( ALAT ) ≤ 5 x ULN renal : creatinine ≤ 1.5 x ULN Signed write informed consent The patient must able comply protocol Evidence metastasis image specimen ( e.g . N1 lymphnode dissection ) Prior ongoing treatment hormone ( antiandrogens , GnRH ) Prior radiotherapy pelvis Previous malignancy prostate cancer basalioma past 5 year . Clinically significant ( i.e . active ) cardiovascular disease e.g . myocardial infarction ( ≤ 6 month ) , unstable angina , New York Heart Association ( NYHA ) grade IIIIV congestive heart failure Severe pulmonary disease e.g . pulmonary fibrosis Any serious uncontrolled illness opinion investigator make undesirable patient enter trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>